Diamonds and Dogs


Small biotech Orexigen Therapeutics (OREX) surged 32% to a four-year high on enormous volume Tuesday on news that its obesity drug might not only make people look better but also help them live longer. Late Monday, Orexigen disclosed that an interim analysis of an ongoing trial looking at cardiovascular events such as heart attacks and strokes in patients on its drug, Contrave found a 41% reduction in events for patients on the drug vs. those on a placebo.  An analyst at Piper increased his price target to $26 from $16 following the patent news. Looks like Orexigen could a diamond for a number of days to come.


Widespread fake ordering, known as "brushing," at the Chinese websites run by Alibaba (BABA) is the latest problem weighing on the stock of China's top e-commerce company, making it our dog of the day. Shares in the company dipped as low as $80.03, the lowest price since Alibaba went public in September, before recovering slightly to close the day at $81.58 down 2.88%. Adding to Alibaba's problems, the Taiwanese government asked Alibaba to withdraw its operations from that country within six months for violating investment rules there. Long term Alibaba should fix these problems, but in the short term the company and stock are under pressure.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.